Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Thymalin vs Thymosin α-1
An educational, source-based comparison of Thymalin and Thymosin α-1 — how each peptide works, what it's researched for, and what to know before going deeper.
A polypeptide complex extracted from calf thymus, studied as an immune bioregulator. Research suggests restoration of T-cell function and thymic activity in aged and immunocompromised cohorts.
- Immunosenescence
- Recovery from infection in elderly cohorts
- Adjunct in chronic inflammatory conditions
- • Approved in Russia; not FDA-approved.
- • Mixture composition is not fully characterized.
A 28-amino-acid peptide naturally produced by the thymus. Research indicates it modulates T-cell maturation, dendritic cell function, and innate immune signaling. Approved in several countries (under the name Zadaxin) as an adjunct in hepatitis B/C and certain cancer protocols.
- Chronic viral hepatitis (approved use abroad)
- Vaccine response augmentation
- Immunosenescence
- Adjunct in oncology research
- • Approved in 35+ countries but not FDA-approved in the US.
- • Generally well tolerated in published clinical data.
- • Requires physician oversight.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Thymalin | Thymalin in geriatric patients: long-term outcomes | Advances in Gerontology | 2014 | Multi-year follow-up reported reduced morbidity and improved immune markers. |
| Thymosin α-1 | Thymosin alpha 1: a comprehensive review of clinical experience | Annals of the New York Academy of Sciences | 2010 | Reviews approved uses and ongoing trials across viral, oncologic, and immune indications. |
Side-effect & safety grid
- Approved in Russia; not FDA-approved.
- Mixture composition is not fully characterized.
- Approved in 35+ countries but not FDA-approved in the US.
- Generally well tolerated in published clinical data.
- Requires physician oversight.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Thymalin vs Thymosin α-1 — Key differences
- Class: Thymalin is classified as Immune · Bioregulator, while Thymosin α-1 is Immune Modulation.
- Primary research focus: Thymalin — immunosenescence; Thymosin α-1 — chronic viral hepatitis (approved use abroad).
- Tag: Immune · Longevity vs Immune.